Keros Therapeutics Inc

NASDAQ:KROS   3:59:52 PM EDT
38.17
+0.07 (+0.18%)
Other Pre-Announcement

Keros Therapeutics Posts Qtrly Loss Per Share $0.49

Published: 03/25/2021 12:34 GMT
Keros Therapeutics Inc (KROS) - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results.
Keros Therapeutics Inc - Qtrly Loss per Share $0.49.
Keros Therapeutics Inc - Cash and Cash Equivalents As of December 31, 2020 Was $265.9 Million.
Keros Therapeutics - Expects Cash & Cash Equivalents It Had on Hand at Dec 31, 2020 Will Fund Operating Expenses and Capex Requirements Into Q4 2023.